CN117083265A - 激酶抑制剂及其用途 - Google Patents

激酶抑制剂及其用途 Download PDF

Info

Publication number
CN117083265A
CN117083265A CN202180084903.0A CN202180084903A CN117083265A CN 117083265 A CN117083265 A CN 117083265A CN 202180084903 A CN202180084903 A CN 202180084903A CN 117083265 A CN117083265 A CN 117083265A
Authority
CN
China
Prior art keywords
optionally substituted
compound
pharmaceutically acceptable
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180084903.0A
Other languages
English (en)
Chinese (zh)
Inventor
陈晨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mosaca Pharmaceuticals
Original Assignee
Bichen Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bichen Pharmaceutical Technology Co ltd filed Critical Bichen Pharmaceutical Technology Co ltd
Publication of CN117083265A publication Critical patent/CN117083265A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180084903.0A 2020-12-16 2021-12-16 激酶抑制剂及其用途 Pending CN117083265A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126364P 2020-12-16 2020-12-16
US63/126,364 2020-12-16
PCT/US2021/063724 WO2022133040A1 (en) 2020-12-16 2021-12-16 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN117083265A true CN117083265A (zh) 2023-11-17

Family

ID=79425572

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180084903.0A Pending CN117083265A (zh) 2020-12-16 2021-12-16 激酶抑制剂及其用途

Country Status (9)

Country Link
US (1) US20240083844A1 (https=)
EP (1) EP4263501A1 (https=)
JP (1) JP2023554391A (https=)
KR (1) KR20230144529A (https=)
CN (1) CN117083265A (https=)
AU (1) AU2021401282A1 (https=)
CA (1) CA3179325A1 (https=)
MX (1) MX2023006434A (https=)
WO (1) WO2022133040A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025184877A1 (zh) * 2024-03-07 2025-09-12 中国医学科学院基础医学研究所 新免疫检查点grhl3在癌症诊疗和免疫治疗疗效评价中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116356017A (zh) * 2022-12-12 2023-06-30 南京腾辰生物科技有限公司 一种甲状腺肿瘤良恶性早期诊断标志物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101065358A (zh) * 2004-10-20 2007-10-31 应用研究系统Ars股份公司 3－芳基氨基吡啶衍生物
US20130252922A1 (en) * 2010-10-29 2013-09-26 Bayer Intellectual Property Gmbh Substituted phenoxypyridines
US20150038481A1 (en) * 2012-05-22 2015-02-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0812913D0 (en) * 2008-07-15 2008-08-20 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN102666512B (zh) * 2009-10-13 2014-11-26 奥斯特姆医疗公司 对疾病治疗有用的mek抑制剂
WO2019006548A1 (en) * 2017-07-04 2019-01-10 Trillium Therapeutics Inc. FLUORINATED 2,4-DIAMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF TYROSINE KINASE MER (MERTK) AND USES THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101065358A (zh) * 2004-10-20 2007-10-31 应用研究系统Ars股份公司 3－芳基氨基吡啶衍生物
US20130252922A1 (en) * 2010-10-29 2013-09-26 Bayer Intellectual Property Gmbh Substituted phenoxypyridines
US20150038481A1 (en) * 2012-05-22 2015-02-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025184877A1 (zh) * 2024-03-07 2025-09-12 中国医学科学院基础医学研究所 新免疫检查点grhl3在癌症诊疗和免疫治疗疗效评价中的应用

Also Published As

Publication number Publication date
EP4263501A1 (en) 2023-10-25
JP2023554391A (ja) 2023-12-27
MX2023006434A (es) 2023-06-13
WO2022133040A1 (en) 2022-06-23
CA3179325A1 (en) 2022-06-23
US20240083844A1 (en) 2024-03-14
KR20230144529A (ko) 2023-10-16
AU2021401282A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
KR102520543B1 (ko) 피리딘 화합물
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
CN107108671B (zh) 作为raf激酶抑制剂的化合物和组合物
EP3684772B1 (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
WO2021249563A1 (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
JP2011515370A (ja) ４−アミノ−５−フルオロ−３−［５−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］キノリン−２（１ｈ）−オン乳酸塩の結晶形態及び２つの溶媒和物形態
HUE031955T2 (en) New pyrrole pyrimidine compounds as inhibitors of protein kinases
JP2020506171A (ja) Ｊａｋ１選択的阻害剤
EP4155304B1 (en) Compound used as ret kinase inhibitor and application thereof
WO2013007184A1 (zh) 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
CN117083265A (zh) 激酶抑制剂及其用途
EP3418277A1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
CN111518082B (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
KR102668390B1 (ko) 신규한 pan-RAF 키나아제 저해제 및 이의 용도
CN109111439B (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
US10301325B2 (en) Quinoline derivative, and pharmaceutical composition, preparation method and use thereof
HK40103623A (zh) 激酶抑制剂及其用途
CN121202878A (zh) 一种c-Met抑制剂及其制备方法和应用
CN115490640A (zh) 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
HK40052813A (en) Pyridine salts and process
JP2024500247A (ja) アミドオキサゾール系化合物
HK40090211B (en) Compound used as ret kinase inhibitor and application thereof
JP2023505690A (ja) 複製タンパク質ａ（ｒｐａ）－ｄｎａ相互作用阻害剤
HK40057704A (en) Aromatic ring-linked dioxane-quinazoline or -quinoline compounds, compositions and use thereof
HK40005148A (en) Pyridine compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103623

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20260414

Address after: Massachusetts, USA

Applicant after: Mosaca Pharmaceuticals

Country or region after: U.S.A.

Address before: California, USA

Applicant before: Bichen Pharmaceutical Technology Co.,Ltd.

Country or region before: U.S.A.